Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report

BMC Gastroenterol. 2019 May 24;19(1):76. doi: 10.1186/s12876-019-0995-z.

Abstract

Background: Chronic hepatitis E represents an emerging challenge in organ transplantation, as there are currently no established treatment options for patients who fail to clear hepatitis E virus (HEV) following reduction of immunosuppressive therapy and/or treatment with ribavirin. Sofosbuvir has shown antiviral activity against HEV in vitro but clinical utility in vivo is unknown.

Case presentation: We describe a 57-year-old liver transplant recipient with decompensated graft cirrhosis due to chronic hepatitis E. Reduction of immunosuppressive treatment as well ribavirin alone for 4 months did not result in viral clearance. Add-on of sofosbuvir for 6 months was associated with HEV RNA becoming undetectable in plasma. However, sustained viral clearance could not be achieved.

Conclusions: Sofosbuvir may have some antiviral activity against HEV when added to ribavirin. However, this did not suffice to yield sustained viral clearance. Our well-characterized observation emphasizes the need for new treatment options to cure chronic hepatitis E in the setting of organ transplantation.

Keywords: Chronic hepatitis; Decompensated cirrhosis; Hepatitis E virus; Rabbit HEV; Solid organ transplantation.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Chronic Disease
  • Drug Therapy, Combination
  • Hepatitis E / complications
  • Hepatitis E / drug therapy*
  • Humans
  • Liver Cirrhosis / physiopathology
  • Liver Cirrhosis / virology*
  • Liver Transplantation
  • Male
  • Middle Aged
  • Postoperative Period
  • Ribavirin / therapeutic use*
  • Sofosbuvir / therapeutic use*

Substances

  • Antiviral Agents
  • Ribavirin
  • Sofosbuvir